Cargando…
Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen
Accumulation of mutant p53 proteins is frequently found in a wide range of cancers. While conventional antibodies fail to target intracellular proteins, proteosomal degradation results in the presentation of p53-derived peptides on the tumour cell surface by class I molecules of the major histocompa...
Autores principales: | Low, Lionel, Goh, Angeline, Koh, Joanna, Lim, Samantha, Wang, Cheng-I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879612/ https://www.ncbi.nlm.nih.gov/pubmed/31772160 http://dx.doi.org/10.1038/s41467-019-13305-z |
Ejemplares similares
-
Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens
por: Gubin, Matthew M., et al.
Publicado: (2014) -
Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumours of astrocytic lineage
por: Pardo, F S, et al.
Publicado: (2004) -
Mutant p53 as an Antigen in Cancer Immunotherapy
por: Sobhani, Navid, et al.
Publicado: (2020) -
Tumour Specific T-Like Antigen of Human Breast Carcinoma
por: Taylor, G., et al.
Publicado: (1970) -
Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
por: Brown, J. M.
Publicado: (1998)